Home / Latest Reports / Paroxysmal Nocturnal Hemoglobinuria Pnh Treatment Market

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market By Treatment - Global Industry Analysis & Forecast to 2027

Published On : November 2018 Pages : 170 Category: Pharma & Healthcare Report Code : HC111922

Request Sample Inquiry Before Buying Request for Customization Check Discount

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market By Treatment (Stem Cell Transplant, Medication, Blood Transfusion) - Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Paroxysmal nocturnal hemoglobinuria (PNH) is a ultra-uncommon blood issue occurring in the stem cells of the bone marrow, which are hereditarily described by the somatic mutation in the phosphatidylinositol glycan protein A (PIG-A) gene. PNH for the most part happens in the mid-30s. Around 10% patients can experience PNH indications at 21 years old or prior. Around 1 to 5 people for every million individuals in the United States are evaluated to experience the ill effects of PNH. Expanding adoption of top notch therapeutics, increasing aged populace, and rise of biologics are probably going to be a portion of the essential development stimulants for the market.

Market Segmentation

Based on treatment, allogeneic stem cell transplantation is the known to be the only effective treatment for PNH patients. Clinical results from different SCT programs reflect that this technique is constrained to a limited number of patients who are suffering from comparative rare issues.

Regional Insights

North America rules the worldwide PNH treatment market because of the ascent in the quantity of blood and bone marrow related illnesses, accessibility of supportive repayment schemes, and increment in awareness about the early identification of the sickness in the area.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis                         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • Akari Therapeutics
  • Ra Pharmaceuticals
  • Alexion Pharmaceuticals
  • Apellis Pharmaceuticals
  • Ra Pharmaceuticals

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2017 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Treatment, Estimates and Forecast, 2017-2027 ($Million)

·         Stem Cell Transplant

·         Medication

·         Blood Transfusion

·         Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

·         North America

§  North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Country

o    U.S. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

·         Europe

§  Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Country

o    Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Rest of Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

·         Asia-Pacific

§  Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Country

o    China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Rest of Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

·         South America

§  South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Columbia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Rest of South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

·         Middle East and Africa

§  Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    UAE Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Nigeria Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

o    Rest of MEA Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

3.3.     SWOT Analysis

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Treatment

5.1.     Introduction

5.2.     Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Market Share by Treatment  (2017-2027)

5.2.1.  Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Revenue Share by Treatment  (2017-2027)

5.3.     Stem Cell Transplant

5.3.1.  Global Stem Cell Transplant Revenue and Growth Rate (2017-2027)

5.4.     Medication

5.4.1.  Global Medication Revenue and Growth Rate (2017-2027)

5.5.     Blood Transfusion

5.5.1.  Global Blood Transfusion Revenue and Growth Rate (2017-2027)

6.       Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Region

6.1.     Introduction

6.2.     Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Market Share by Regions

6.2.1.  Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Regions (2017-2027)

6.3.     North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Countries

6.3.1.  North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Growth Rate (2017-2027)

6.3.2.  North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) by Countries (2017-2027)

6.3.3.  United States

6.3.3.1.  United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.3.4.  Canada

6.3.4.1.  Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.3.5.  Mexico

6.3.5.1.  Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.     Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Countries

6.4.1.  Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Growth Rate (2017-2027)

6.4.2.  Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) by Countries (2017-2027)

6.4.3.  Germany

6.4.3.1.  Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.4.  France

6.4.4.1.  France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.5.  UK

6.4.5.1.  UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.6.  Russia

6.4.6.1.  Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.7.  Italy

6.4.7.1.  Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.8.  Rest of Europe

6.4.8.1.  Rest of Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.     Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Countries

6.5.1.  Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Growth Rate (2017-2027)

6.5.2.  Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) by Countries (2017-2027)

6.5.3.  China

6.5.3.1.  China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.4.  Japan

6.5.4.1.  Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.5.  Korea

6.5.5.1.  Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.6.  India

6.5.6.1.  India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.7.  Southeast Asia

6.5.7.1.  Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.8.  Rest of Asia-Pacific

6.5.8.1.  Rest of Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.     South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Countries

6.6.1.  South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Growth Rate (2017-2027)

6.6.2.  South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) by Countries (2017-2027)

6.6.3.  Brazil

6.6.3.1.  Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.4.  Argentina

6.6.4.1.  Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.5.  Columbia

6.6.5.1.  Columbia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.6.  Rest of South America

6.6.6.1.  Rest of South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.     Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Countries

6.7.1.  Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Growth Rate (2017-2027)

6.7.2.  Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) by Countries (2017-2027)

6.7.3.  Saudi Arabia

6.7.3.1.  Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.4.  United Arab Emirates

6.7.4.1.  United Arab Emirates Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.5.  Egypt

6.7.5.1.  Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.6.  Nigeria

6.7.6.1.  Nigeria Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.7.  South Africa

6.7.7.1.  South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.8.  Turkey

6.7.8.1.  Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.9.  Rest of Middle East and Africa

6.7.9.1.  Rest of Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

7.       Company Profiles

7.1.     Akari Therapeutics

7.1.1.  Business Overview

7.1.2.   Service Portfolio

7.1.3.  Strategic Developments

7.1.4.   Revenue and Market Share

7.2.     Ra Pharmaceuticals

7.2.1.  Business Overview

7.2.2.   Service Portfolio

7.2.3.  Strategic Developments

7.2.4.   Revenue and Market Share

7.3.     Alexion Pharmaceuticals

7.3.1.  Business Overview

7.3.2.   Service Portfolio

7.3.3.  Strategic Developments

7.3.4.   Revenue and Market Share

7.4.     Apellis Pharmaceuticals

7.4.1.  Business Overview

7.4.2.   Service Portfolio

7.4.3.  Strategic Developments

7.4.4.   Revenue and Market Share

7.5.     Ra Pharmaceuticals

7.5.1.  Business Overview

7.5.2.   Service Portfolio

7.5.3.  Strategic Developments

7.5.4.   Revenue and Market Share

8.       Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competition, by Manufacturer

8.1.     Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Market Share by Manufacturer (2017-2017)

8.2.     Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price By Region (2017-2017)

8.3.     Top 5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturer Market Share

8.4.     Market Competition Trend

9.       Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.1.     Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2027)

9.2.     Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast by Regions (2017-2027)

9.2.1.  North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.1.1.  United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.1.2.  Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.1.3.  Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.2.  Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.2.1.  Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.2.2.  France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.2.3.  UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.2.4.  Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.2.5.  Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.2.6.  Rest of Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.3.  Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.3.1.  China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.3.2.  Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.3.3.  Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.3.4.  India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.3.5.  Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.3.6.  Rest of Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.4.  South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.4.1.  Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.4.2.  Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.4.3.  Columbia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.4.4.  Rest of South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.5.  Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.5.1.  Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.5.2.  United Arab Emirates Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.5.3.  Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.5.4.  Nigeria Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.5.5.  South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.5.6.  Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.2.5.7.  Rest of Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2017-2027)

9.3.     Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast by Treatment  (2017-2027)

9.3.1.  Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Treatment  (2017-2027)

9.3.2.  Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share Forecast by Treatment  (2017-2027)

List of Tables

List of Tables and Figures:

Figure United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Revenue Share by Treatment (2017-2018)
Figure Global Stem Cell Transplant Revenue and Growth Rate (2017-2018)
Figure Global Medication Revenue and Growth Rate (2017-2018)
Figure Global Blood Transfusion Revenue and Growth Rate (2017-2018)
Table Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue by Regions (2017-2018)
Figure North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Growth Rate (2017-2018)
Figure North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Countries (2017-2018)
Figure North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) by Countries (2017-2018)
Figure United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Growth Rate (2017-2018)
Figure Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Countries (2017-2018)
Figure Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Rest of Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Countries (2017-2018)
Figure Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) by Countries (2017-2018)
Figure China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Growth Rate (2017-2018)
Figure South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Countries (2017-2018)
Figure South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Columbia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Rest of South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Countries (2017-2018)
Figure Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure United Arab Emirates Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Nigeria Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Table Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Ra Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Alexion Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Ra Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share by Manufacturer
Figure Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue and Market Share by Manufacturer
Table Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Price by Region (2017-2017)
Figure Top 5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Revenue (Millions USD) and Growth Rate (2018-2025)
Table Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast by Regions (2018-2025)
Figure North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Rest of Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Columbia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Rest of South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure United Arab Emirates Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Nigeria Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Forecast (2018-2025)
Figure Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Treatment (2018-2025)
Figure Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share Forecast by Treatment (2018-2025)
Figure Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Forecast by Treatment (2018-2025)

Please Note: Data related to the Companies are subject to Availability.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*